Biogen

4Q Revenues: $2.5 billion (+3%)

4Q Earnings: $267 million (+7%)

FY Revenues: $9.7 billion (-2%)

FY Earnings: $1.6 billion (+41%)

Comments: Revenue from product launches offset decline in multiple sclerosis product revenue, down 8% to $1.1 billion. Tecfidera sales were $227.8 million, down 7% and Vumerity sales were $176.6 million, up 13%. Avonex sales were $170 million, down 17%. Tysabri sales were $415.4 million, down 11%.

Rare Disease revenue was $535.3 million in the quarter, up 13%. Spinraza sales were $421.4 million, up 2%. Global Skyclarys revenue was $102.2 million in the quarter, compared to $56 million 4Q23, nearly doubling the number of patients on therapy globally; U.S. Skyclarys revenue of approximately $71 million was impacted by inventory and Medicare discount dynamics. Skyclarys was obtained as part of the acquisition of Reata in September 2023. 

Biosimilars sales were $201.5 million, up 7% driven by Benepali, with sales of $125 million, up 16%.

LEQEMBI global in-market sales in the quarter were approximately $87 million, including U.S. in-market sales of approximately $50 million.